Last checked at 30 Mar 2009 10:03
| For immediate release | 30 March 2009 |
ALLIANCE PHARMA PLC
("the Company")
Share Purchase
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was informed on 27 March 2009 that MVM Life Science Partners LLP ("MVM") purchased 1,000,000 Convertible Unsecured Loan Stock of £1 each ("CULS") in the Company on 27 March 2009 at a price of 56.5p per £1 unit. MVM's resultant interest in the Company is 1,000,000 CULS, equivalent to 13.33 per cent of the issued CULS, and 15,000,000 ordinary shares, equivalent to 9.26 per cent of the issued share capital. The CULS carry an option to convert into ordinary shares in the Company at a price of 21p per share at any time up to 30 November 2013. If the CULS held by MVM were converted into ordinary shares, MVM would hold 19,761,905 ordinary shares in the Company, equivalent to 11.85 per cent of the enlarged issued share capital.
Thomas Casdagli, a non-executive director of the Company, is a partner in MVM and therefore has a non-beneficial interest in the CULS and ordinary shares of the Company that are held by MVM.
For further information:
| Alliance Pharma plc | + 44 (0) 1249 466966 |
| John Dawson, Chief Executive | |
| Richard Wright, Finance Director | |
| www.alliancepharma.co.uk | |
| Buchanan Communications | + 44 (0) 20 7466 5000 |
| Mark Court / Rebecca Skye Dietrich / Stasa Filiplic | |
| Numis Securities Limited | + 44 (0) 20 7260 1000 |
| Nominated Adviser: Michael Meade / Brent Nabbs | |
| Corporate Broking: David Poutney |